x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Multidisciplinary Approach to Diagnosing and Managing...

CME/CE ·

2024/04/24

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of

en

00:00:00

Managing Indolent Systemic Mastocytosis: A...

CME/CE ·

2024/04/24

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and

en

00:00:00

Diagnosing ATTRv-PN: What's in Your Toolbox?

CME/CE ·

2024/04/23

Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and

en

00:00:00

Shh…Gene-Silencing Therapies for ATTRv-PN

CME/CE ·

2024/04/23

Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold

en

00:00:00

ATTRv-PN: A Family Affair?

CME/CE ·

2024/04/23

Guest: John Berk, MD Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for

en

00:00:00

Advancing the Treatment of ATTRv-PN: What's in the...

CME/CE ·

2024/04/23

Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN

en

00:00:00

ATTRv-PN: A Complicated Disease With a Poor Prognosis

CME/CE ·

2024/04/23

Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN

en

00:00:00

The Multiple Faces of ATTRv-PN

CME/CE ·

2024/04/23

Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold

en

00:00:00

Raising the Red Flag: What's Your Index of Suspicion...

CME/CE ·

2024/04/23

Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold

en

00:00:00

ATTR Amyloidosis: Familial Vs Wild-Type

CME/CE ·

2024/04/23

Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the

en

00:00:00

Beyond BeAT-HF: Integrating Barostim into a...

CME/CE ·

2024/04/05

Host: Dmitry M. Yaranov, MD During the clinical course of heart failure, even with guideline directed medical therapy, many patients still experience symptoms that negatively impact their quality of life. Baroreflex activation therapy, or BAT, is an FDA approved therapy for patients with heart failure with reduced ejection fraction that has been shown to improve patient’s functional status, exercise capacity, and quality of life. Let's review how we may be able to expand the window of

en

00:00:00

Overcoming Acquired TKI-Resistance with...

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH Host: Alexander Drilon, MD This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

Safety and Tolerability of ROS1 Tyrosine Kinase...

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

First-Line Targeted Therapies for ROS1...

CME/CE ·

2024/03/01

Host: Alexander Drilon, MD This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

Current Guidelines and Real-World Evidence for ROS1...

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

Case: Treatment Selection for ROS1-Rearranged NSCLC...

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH Host: Alexander Drilon, MD This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

Treatment Strategy of ROS1-Rearranged NSCLC in...

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH Host: Alexander Drilon, MD This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

Later-Line Targeted Therapies for ROS1...

CME/CE ·

2024/03/01

Host: Alexander Drilon, MD This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

The Role of Chemotherapy and Immunotherapy in...

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH Host: Alexander Drilon, MD This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

00:00:00

Intracranial Activity of ROS1 TKIs

CME/CE ·

2024/03/01

Host: Charu Aggarwal, MD, MPH This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

en

267 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事